3 Stocks That Dropped Despite the Soaring Dow

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Economic strength and strong earnings add up to a powerful combination for the financial markets, and today, it proved too powerful a combination for the stock market to resist. With new gains reported from the housing industry, and signs of improvement on the employment front, optimism that the economy may finally start to fire up encouraged investors to bid the broader market up to new five-year highs. The Dow Jones Industrials (DJINDICES: ^DJI  ) gave up some of its gains near the close, but still finished up 85 points.

But on the earnings front, some stocks weren't able to participate in the rally. Within the Dow, Bank of America (NYSE: BAC  ) plunged more than 4%, after reporting earnings this morning. Thanks to a whopping $4.7 billion in settlements with Fannie Mae and banking regulators, B of A was just barely able to scrape up a profit of $0.03 per share. Given how far short that fell of results from other banks earlier this week, it's not surprising that investors were disappointed, especially after the stock more than doubled in 2012 in anticipation of a stronger recovery.

Elsewhere, Leap Wireless (UNKNOWN: LEAP.DL  ) fell nearly 7%, after negative comments from analysts at Jefferies. The analyst report said that the prepaid wireless business faces huge new competitive pressures from traditional postpaid providers, especially as high-end smartphones become available at little upfront cost under two-year contracts. Moreover, with efforts to make the most of already available spectrum, it's unclear whether Leap can monetize its spectrum holdings, which have constituted a significant part of its overall value. Leap shares have been volatile, as different analysts have weighed in on both sides of this issue.

Finally, weight-loss drug maker VIVUS (NASDAQ: VVUS  ) fell 4%, after it got downgraded by analysts at Brean Capital. Although the company issued a report on shipments of its Qsymia drug that led to a 10% gain for the shares earlier this month, it's still very early, and VIVUS will have to continue to work hard to encourage adoption by doctors before rival Arena Pharmaceuticals' (NASDAQ: ARNA  ) Belviq drug gets approval and starts competing. For its part, Arena finished unchanged, after soaring as much as 3.5% earlier in the day, on optimism about the news. The fact is that the potential market for obesity drugs is big enough that both players could succeed; but VIVUS definitely should make the most of its first-mover advantage.

Don't miss these winners
If you're tired of settling for losing stocks, let Motley Fool co-founder David Gardner show you the way to stocks with impressive growth potential. Right now, David has opened the doors to his Supernova service, and you can take advantage of a limited-time offer to take a tour of the service. But don't wait; click here to get instant access before Supernova closes its doors to new customers.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 18, 2013, at 7:37 AM, RSRdriver wrote:

    It is very early days for Vivus and Qysimia.To make the determinations that the last few articles seem to make is stupid. Right now and for the near future, VVUS is all that will be available THAT DOES WHAT IT WAS MADE TO DO- Cause weight loss!

    Try to imagine a drug that does not work (ARNA BELVIQ) with the same problems and you can see the coming fate of Arena!

    OREX looks better and better every day.

    And another thing! Flagboy over on Seeking Alpo commenting on the Street/Motley situation of the last few days is hilarious. Someone should ask him why for the about the last 8 months he has come out with at least 2 pieces a week pumping ARNA. Not to mention, all the time quieting dissent with banishment or removing your post entirely! Meanwhile the same Areniac posts and attacks seen in Adam's article are allowed and all so Flagboy can increase his follwers from the lowly amount of four! That' right 4. Not to mention his known long position in ARNA!

    Motley Fool and particularly Seeking Alpha had better clean house of these abusers soon or loose any credibility they still may have!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2202930, ~/Articles/ArticleHandler.aspx, 9/27/2016 10:09:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 53 minutes ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
ARNA $1.81 Up +0.08 +4.62%
Arena Pharmaceutic… CAPS Rating: ***
BAC $15.29 Up +0.20 +1.33%
Bank of America CAPS Rating: ****
LEAP.DL $0.00 Down +0.00 +0.00%
Leap Wireless Inte… CAPS Rating: *
VVUS $1.20 Down -0.04 -3.23%
VIVUS CAPS Rating: **